Crossmark

Protocol implementation during the COVID-19 pandemic: experiences from a randomized trial of stress ulcer prophylaxis

Crossref DOI link: https://doi.org/10.1186/s12874-024-02233-2

Published Online: 2024-05-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dennis, Brittany

Deane, Adam

Lauzier, François

Zytaruk, Nicole

Hardie, Miranda

Hammond, Naomi

Finfer, Simon

Arabi, Yaseen

Marshall, John

Saunders, Lois

Heels-Ansdell, Diane

Myburgh, John

Knowles, Serena

Muscedere, John

Ostermann, Marlies

Rajbhandari, Dorrilyn

English, Shane

Matic, Karlo

Venkatesh, Bala

Al Fares, Abdulrahman

Guyatt, Gordon

Alhazzani, Waleed

Mumtaz, Hassan

Poole, Alexis

Xie, Feng

Thabane, Lehana

Hall, Richard

Cook, Deborah
Funding

Funding for this research was provided by:

Canadian Institutes of Health Research (202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215, 202207CL3-492565-CTP-CEBA-19215)

Physicians' Services Incorporated Foundation (R2-33, R2-33, R2-33, R2-33)

Hamilton Academy of Health Sciences Organization (HAH-22-009, HAH-22-009, HAH-22-009, HAH-22-009, HAH-22-009, HAH-22-009, HAH-22-009, HAH-22-009, HAH-22-009, HAH-22-009, HAH-22-009)
License Information

Text and Data Mining valid from 2024-05-04

Version of Record valid from 2024-05-04
More Information

Article History

Received: 13 June 2023

Accepted: 23 April 2024

First Online: 4 May 2024

Declarations

:

: The Hamilton Integrated Research Ethics Board (HiREB) approved the REVISE trial. REVISE was also approved by relevant research ethics committees as required in each jurisdiction. All experiments were performed in accordance with relevant guidelines and regulations. Informed consent models approved for REVISE pre-pandemic included a priori consent and consent to continue. Where possible, informed a priori consent was obtained for all participants or their substitute decision maker. Consent to continue models were also employed. In cases where participants were unable to provide consent and lacked a substitute decision maker, consent to continue models were employed. Not all participants are able to provide informed consent given the nature of the included population.

: Not applicable for this publication. REVISE is a trial endorsed by the ANZICS-Clinical Trials Group and the Canadian Critical Care Trials Group.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below